Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma
Abstract Background Urothelial carcinoma (UC) is an aggressive malignancy with limited options for patients unresponsive to chemotherapy or immunotherapy. Disitamab vedotin (RC48), a HER2-targeted antibody-drug conjugate(ADC), has shown promising results in clinical trials, but real-world data are l...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2025-11-01
|
| Seri Bilgileri: | BMC Urology |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s12894-025-01960-y |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|